Archives20242023202220212020201920182017201620152014201320122011 September 30, 2022INTERIM RESULTS for the six months ended 30 June 2022 Read More September 15, 2022Written response received from the FDA Read More September 07, 2022Exercise of Options | L1 Capital Read More August 31, 2022FDA response for Type C Meeting – update Read More August 31, 2022Exercise of Options Read More August 24, 2022Exercise of Options Read More August 18, 2022Lanstead Capital TR1 Read More May 04, 2022UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More February 07, 2022LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More January 10, 2022TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022) Read More January 10, 2022TR1 – Luca Associates – Major Holdings in Shares (4 January 2022) Read More 123456…14
April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
February 07, 2022LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More